Doer Biologics
Suzhou, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage company advancing a pipeline of antibody therapies for oncology and immunology.
OncologyImmunology
Technology Platform
A proprietary platform for the design and development of monoclonal and bispecific antibodies with tailored functional properties.
Opportunities
Early clinical success could position the company for lucrative licensing deals or further funding rounds.
Risk Factors
Clinical hold or unexpected toxicity in first-in-human trials, which could derail development and investor confidence.
Competitive Landscape
Enters a crowded clinical trial environment for antibody therapies, where demonstrating superior efficacy or safety is crucial.